Trial Profile
Phase II Trial, Multicenter, First Line Paclitaxel-Avelumab Treatment for Inoperable Angiosarcoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Paclitaxel (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- Acronyms ASAP
- 10 Jul 2018 Status changed from not yet recruiting to recruiting.
- 04 May 2018 New trial record